Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $6.35M | $22.4M | — | — | — | — | — |
| Revenue growth | — | — | 252.6% | — | — | — | — | — |
| Operating income | -$23.2M | -$37.5M | -$41.2M | -$70.8M | -$75.9M | -$67.6M | -$59.7M | -$57.6M |
| Operating margin | — | -590.5% | -184.2% | — | — | — | — | — |
| Net income | -$22.8M | -$33.7M | -$36.6M | -$69.4M | -$74.7M | -$62.7M | -$55.7M | -$55.8M |
| Net margin | — | -531.5% | -163.6% | — | — | — | — | — |
| EPS (diluted) | -$16.64 | -$2.15 | -$1.33 | -$2.51 | -$2.69 | -$2.25 | -$23.88 | -$19.65 |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $7.99M | -$35.6M | -$45.0M | -$57.3M | -$53.9M | -$53.0M | -$40.8M | -$49.6M |
| Capital expenditures | $3.06M | $3.37M | $7.13M | $2.36M | $2.12M | $820K | $474K | — |
| Free cash flow | $4.93M | -$39.0M | -$52.1M | -$59.6M | -$56.0M | -$53.8M | -$41.3M | — |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $135M | $34.1M | $32.8M | $12.3M | $26.6M | $13.1M | $27.7M | $26.0M |
| Total assets | $148M | $356M | $307M | $242M | $184M | $128M | $80.9M | $50.2M |
| Total liabilities | $32.3M | $34.7M | $12.9M | $9.00M | $16.6M | $13.6M | $15.4M | $15.2M |
| Long-term debt | $460K | $5.00M | $3.47M | $0.00 | $0.00 | — | — | — |
| Shareholders' equity | -$46.9M | $321M | $294M | $233M | $168M | $114M | $65.5M | $34.9M |
| Retained earnings | -$47.3M | -$81.0M | -$118M | -$187M | -$262M | -$324M | -$380M | -$436M |
| Shares (wtd avg diluted) | 1.37M | 15.6M | 27.5M | 27.6M | 27.7M | 27.8M | 2.33M | 2.84M |
Every figure is extracted from NextCure, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.